Literature DB >> 29044882

Sox2 Communicates with Tregs Through CCL1 to Promote the Stemness Property of Breast Cancer Cells.

Yingxi Xu1,2, Xiaoli Dong1, Pingping Qi1, Yujie Ye1, Wenzhi Shen1, Liang Leng1, Lina Wang1,2, Xuefei Li1,3, Xiaohe Luo1, Yanan Chen1, Peiqing Sun4, Rong Xiang1,5,6, Na Li5,6,7.   

Abstract

As an important component of the tumor microenvironment, CD4+ CD25+ Tregs reduce antitumor immunity, promote angiogenesis and metastasis in breast cancer. However, their function in regulating the "stemness" of tumor cells and the communication between Tregs and cancer stem cells (CSCs) remain elusive. Here, we disclose that the primarily cultured Tregs isolated from breast-tumor-bearing Foxp3-EGFP mouse upregulate the stemness property of breast cancer cells. Tregs increased the side-population and the Aldehyde dehydrogenase-bright population of mouse breast cancer cells, promoted their sphere formation in a paracrine manner, and enhanced the expression of stemness genes, such as Sox2 and so forth. In addition, Tregs increased tumorigenesis, metastasis, and chemoresistance of breast cancer cells. Furthermore, Sox2-overexpression tumor cells activated NF-κB-CCL1 signaling to recruit Tregs through reducing the binding of H3K27Me3 on promoter regions of p65 and Ccl1. These findings reveal the functional interaction between Tregs and CSCs and indicate that targeting on the communication between them is a promising strategy in breast cancer therapy. Stem Cells 2017;35:2351-2365.
© 2017 AlphaMed Press.

Entities:  

Keywords:  CCL1; Cancer stem cells; NF-κB; Sox2; Tregs

Mesh:

Substances:

Year:  2017        PMID: 29044882      PMCID: PMC5958902          DOI: 10.1002/stem.2720

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  44 in total

1.  Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome.

Authors:  Michael Gobert; Isabelle Treilleux; Nathalie Bendriss-Vermare; Thomas Bachelot; Sophie Goddard-Leon; Vanessa Arfi; Cathy Biota; Anne Claire Doffin; Isabelle Durand; Daniel Olive; Solène Perez; Nicolas Pasqual; Christelle Faure; Isabelle Ray-Coquard; Alain Puisieux; Christophe Caux; Jean-Yves Blay; Christine Ménétrier-Caux
Journal:  Cancer Res       Date:  2009-02-24       Impact factor: 12.701

2.  Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells.

Authors:  Purevdorj B Olkhanud; Dolgor Baatar; Monica Bodogai; Fran Hakim; Ronald Gress; Robin L Anderson; Jie Deng; Mai Xu; Susanne Briest; Arya Biragyn
Journal:  Cancer Res       Date:  2009-06-30       Impact factor: 12.701

3.  Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege.

Authors:  Takashi Ishida; Toshihiko Ishii; Atsushi Inagaki; Hiroki Yano; Hirokazu Komatsu; Shinsuke Iida; Hiroshi Inagaki; Ryuzo Ueda
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

Review 4.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer.

Authors:  Dandan Lv; Yan Zhang; Ha-Jeong Kim; Lixing Zhang; Xiaojing Ma
Journal:  Cell Mol Immunol       Date:  2013-02-04       Impact factor: 11.530

5.  Tumor-derived γδ regulatory T cells suppress innate and adaptive immunity through the induction of immunosenescence.

Authors:  Jian Ye; Chunling Ma; Eddy C Hsueh; Christopher S Eickhoff; Yanping Zhang; Mark A Varvares; Daniel F Hoft; Guangyong Peng
Journal:  J Immunol       Date:  2013-01-25       Impact factor: 5.422

6.  Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs.

Authors:  Arya Biragyn; Monica Bodogai; Purevdorj B Olkhanud; Sinan R Denny-Brown; Nitin Puri; Koichi Ayukawa; Shiro Kanegasaki; Cory M Hogaboam; Katarzyna Wejksza; Catalina Lee-Chang
Journal:  J Immunother       Date:  2013-05       Impact factor: 4.456

7.  Intratumoral FOXP3 expression in infiltrating breast carcinoma: Its association with clinicopathologic parameters and angiogenesis.

Authors:  Sachin Gupta; Kusum Joshi; J D Wig; Sunil K Arora
Journal:  Acta Oncol       Date:  2007       Impact factor: 4.089

8.  TAZ is required for metastatic activity and chemoresistance of breast cancer stem cells.

Authors:  M Bartucci; R Dattilo; C Moriconi; A Pagliuca; M Mottolese; G Federici; A Di Benedetto; M Todaro; G Stassi; F Sperati; M I Amabile; E Pilozzi; M Patrizii; M Biffoni; M Maugeri-Saccà; S Piccolo; R De Maria
Journal:  Oncogene       Date:  2014-02-17       Impact factor: 9.867

9.  Possible involvement of CCL1-CCR8 interaction in lymphocytic recruitment in IgG4-related sclerosing cholangitis.

Authors:  Yoh Zen; Rodrigo Liberal; Yasuni Nakanuma; Nigel Heaton; Bernard Portmann
Journal:  J Hepatol       Date:  2013-06-25       Impact factor: 25.083

10.  STIM1 accelerates cell senescence in a remodeled microenvironment but enhances the epithelial-to-mesenchymal transition in prostate cancer.

Authors:  Yingxi Xu; Shu Zhang; Haiying Niu; Yujie Ye; Fen Hu; Si Chen; Xuefei Li; Xiaohe Luo; Shan Jiang; Yanhua Liu; Yanan Chen; Junying Li; Rong Xiang; Na Li
Journal:  Sci Rep       Date:  2015-08-10       Impact factor: 4.379

View more
  26 in total

Review 1.  Chemokine signaling in cancer-stroma communications.

Authors:  Arun J Singh; Joe W Gray
Journal:  J Cell Commun Signal       Date:  2021-06-04       Impact factor: 5.782

Review 2.  Reprogramming the tumor microenvironment to improve the efficacy of cancer immunotherapies.

Authors:  Jabar A Faraj; Ali Jihad Hemid Al-Athari; Sharaf El Din Mohie; Iman Kareem Kadhim; Noor Muhsen Jawad; Weaam J Abbas; Abduladheem Turki Jalil
Journal:  Med Oncol       Date:  2022-09-29       Impact factor: 3.738

Review 3.  Tumor-Associated Inflammation: The Tumor-Promoting Immunity in the Early Stages of Tumorigenesis.

Authors:  Qing Bi; Ji-Yue Wu; Xue-Meng Qiu; Jian-Dong Zhang; Ze-Jia Sun; Wei Wang
Journal:  J Immunol Res       Date:  2022-06-13       Impact factor: 4.493

Review 4.  The tumor microenvironment as driver of stemness and therapeutic resistance in breast cancer: New challenges and therapeutic opportunities.

Authors:  Umar Mehraj; Rais A Ganai; Muzafar A Macha; Abid Hamid; Mohammed A Zargar; Ajaz A Bhat; Mohd Wasim Nasser; Mohammad Haris; Surinder K Batra; Bader Alshehri; Raid Saleem Al-Baradie; Manzoor A Mir; Nissar Ahmad Wani
Journal:  Cell Oncol (Dordr)       Date:  2021-09-16       Impact factor: 6.730

5.  Reprogramming Transcription Factors Oct4 and Sox2 Induce a BRD-Dependent Immunosuppressive Transcriptome in GBM-Propagating Cells.

Authors:  Tengjiao Ma; Chengchen Hu; Bachchu Lal; Weiqiang Zhou; Yongxin Ma; Mingyao Ying; Panagiotis Prinos; Alfredo Quiñones-Hinojosa; Michael Lim; John Laterra; Yunqing Li
Journal:  Cancer Res       Date:  2021-02-11       Impact factor: 13.312

6.  2B4 costimulatory domain enhancing cytotoxic ability of anti-CD5 chimeric antigen receptor engineered natural killer cells against T cell malignancies.

Authors:  Yingxi Xu; Qian Liu; Mengjun Zhong; Zhenzhen Wang; Zhaoqi Chen; Yu Zhang; Haiyan Xing; Zheng Tian; Kejing Tang; Xiaolong Liao; Qing Rao; Min Wang; Jianxiang Wang
Journal:  J Hematol Oncol       Date:  2019-05-16       Impact factor: 17.388

7.  SOX2 promotes hypoxia-induced breast cancer cell migration by inducing NEDD9 expression and subsequent activation of Rac1/HIF-1α signaling.

Authors:  Yueyuan Wang; Maria Bibi; Pengxiang Min; Wenjie Deng; Yujie Zhang; Jun Du
Journal:  Cell Mol Biol Lett       Date:  2019-08-22       Impact factor: 5.787

8.  Increased Expression Of SOX2 Predicts A Poor Prognosis And Promotes Malignant Phenotypes In Upper Tract Urothelial Carcinoma.

Authors:  Zhengqing Bao; Yonghao Zhan; Shiming He; Yifan Li; Bao Guan; Qun He; Xinyu Yang; Xuesong Li; Dong Fang; Liqun Zhou
Journal:  Cancer Manag Res       Date:  2019-10-24       Impact factor: 3.989

Review 9.  Cancer stem cell-immune cell crosstalk in tumour progression.

Authors:  Defne Bayik; Justin D Lathia
Journal:  Nat Rev Cancer       Date:  2021-06-08       Impact factor: 60.716

Review 10.  Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.

Authors:  Luise Müller; Antje Tunger; Ioana Plesca; Rebekka Wehner; Achim Temme; Dana Westphal; Friedegund Meier; Michael Bachmann; Marc Schmitz
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.